Denmark's biotech industry ranks 3rd in Europe  

2009.06.15
A new report from Ernst & Young shows that Denmark has retained its 3rd position in Europe in terms of the number of pharmaceutical products under development
A new report from Ernst & Young, Beyond borders: Global Biotechnology report 2009, shows that Denmark has retained its 3rd position in Europe in terms of the number of pharmaceutical products under development, reports professional journal Ingeniøren (The Engineer). With 135 drug candidates under development, Denmark is only headed in volume terms by Great Britain and Germany.
 
Senior analyst at Ernst & Young Lisa Almén says: "It is very impressive. Denmark lies ahead of several countries with a larger number of companies such as France, and that tells you something about how clever Danish companies are at finding drug candidates," adding that it also gives Denmark a 1st position in terms of products per capita.
 
Lisa Almén considers the high ranking a benefit when Danish companies are trying to attract attention from foreign investors and companies with a view to entering partnerships.
 
"In the long term it can result in more jobs, and that the biotech industry will help accelerate the fine growth in pharmaceutical exports. Hopefully it will also soon result in us seeing a Danish biotech company with many successful drugs on the market."
 
Denmark also increased the number of drug candidates under development by 15% from 2007 to 2008, and the share of product candidates in the crucial final phase of development increased from 5% to 11%.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×